ReviewCurrent treatment options in oncology2013
Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Review in Current treatment options in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- OncoTrace-TOO: Interpretable Machine Learning Framework for Cancer Tissue-of-Origin Identification Using Transcriptomic Signatures.Cancer reports (Hoboken, N.J.) · 2025Article
- Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data.Cancer discovery · 2024Article
- Classification of tumor types using XGBoost machine learning model: a vector space transformation of genomic alterations.Journal of translational medicine · 2023Article
- DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues.Nature communications · 2023Article
- Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping.Genome medicine · 2023Article
- Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features.Nature communications · 2022Article
- CancerNet: a unified deep learning network for pan-cancer diagnostics.BMC bioinformatics · 2022Article
- Cancer Type Classification in Liquid Biopsies Based on Sparse Mutational Profiles Enabled through Data Augmentation and Integration.Life (Basel, Switzerland) · 2021Article
- Real-world data analysis of patients with cancer of unknown primary.Scientific reports · 2021Article
- Deep learning in cancer diagnosis, prognosis and treatment selection.Genome medicine · 2021Review
- Out of Sight, Not Out of Mind.Journal of hospital medicine · 2021Article
- Axillary Nodal Metastases from Carcinoma of Unknown Primary (CUPAx): Role of Contrast-Enhanced Spectral Mammography (CESM) in Detecting Occult Breast Cancer.Journal of personalized medicine · 2021Article
- Artificial Intelligence in Cancer Research and Precision Medicine.Cancer discovery · 2021Review
- CORR Insights®: Does PET/CT Aid in Detecting Primary Carcinoma in Patients with Skeletal Metastases of Unknown Primary?Clinical orthopaedics and related research · 2020Article
- A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.Nature communications · 2020Article
- Comparing Artificial Intelligence Platforms for Histopathologic Cancer Diagnosis.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019Article
- Passenger mutations accurately classify human tumors.PLoS computational biology · 2019Article
- Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation.OncoTargets and therapy · 2019Article
- Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy.SAGE open medical case reports · 2019Article
- The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study.PharmacoEconomics - open · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementCancer of unknown primary site (CUP) is a clinicopathologic syndrome consisting of many types of cancer and accounting for approximately 3 % of all patients with advanced cancers. This syndrome has frustrated patients and physicians for decades, because a primary site or tissue of origin has not been possible to identify clinically, despite the presence of metastatic tumor. Favorable subsets (approximately 20 % of all CUP) with a presumptive occult primary site have been recognized for several decades based on clinical and standard pathologic features; site-specific therapy in these patients improves their survival compared with the majority of other (approximately 80 %) CUP patients. These other patients, most with adenocarcinomas, have been difficult to treat because the tissue of origin was unknown. Broad-spectrum empiric chemotherapy became the standard approach for these patients in the past 30 years. More recently, new diagnostic technology (evolving immunohistochemistry and emergent gene-expression profiling) has enabled us to establish accurately a tissue of origin in most (90 %+) CUP patients. Gene-expression profiling assays complement standard pathology and for the majority of biopsy specimens accurately identify the primary site or tissue of origin; clinical studies have supported the value of site-directed therapy. When the tissue of origin is in doubt after standard pathologic examination, a gene expression assay is frequently diagnostic, and the outcome of many CUP patients is improved with site-specific therapy. The era of empiric therapy has ended in favor of site-specific therapy, based on the precise diagnosis of the tumor type present in each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.